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Charcot-Marie-Tooth (CMT) disease is the most common inherited motor and sensory neuropathy. The axonal
form of the disease is designated as “CMT type 2” (CMT2). Although four loci known to be implicated in autosomal
dominant CMT2 have been mapped thus far (on 1p35-p36, 3q13.1, 3q13-q22, and 7p14), no one causative gene
is yet known. A large Russian family with CMT2 was found in the Mordovian Republic (Russia). Affected members
had the typical CMT2 phenotype. Additionally, several patients suffered from hyperkeratosis, although the asso-
ciation, if any, between the two disorders is not clear. Linkage with the CMT loci already known (CMT1A, CMT1B,
CMT2A, CMT2B, CMT2D, and a number of other CMT-related loci) was excluded. Genomewide screening
pinpointed the disease locus in this family to chromosome 8p21, within a 16-cM interval between markers D8S136
and D8S1769. A maximum two-point LOD score of 5.93 was yielded by a microsatellite from the 5′ region of the
neurofilament-light gene (NF-L). Neurofilament proteins play an important role in axonal structure and are im-
plicated in several neuronal disorders. Screening of affected family members for mutations in the NF-L gene and
in the tightly linked neurofilament-medium gene (NF-M) revealed the only DNA alteration linked with the disease:
a A998C transversion in the first exon of NF-L, which converts a conserved Gln333 amino acid to proline. This
alteration was not found in 180 normal chromosomes. Twenty unrelated CMT2 patients, as well as 26 others with
an undetermined form of CMT, also were screened for mutations in NF-L, but no additional mutations were found.
It is suggested that Gln333Pro represents a rare disease-causing mutation, which results in the CMT2 phenotype.
Introduction
Charcot-Marie-Tooth neuropathy (CMT) is one of the
most common hereditary disorders, affecting 10–40/
100,000 individuals, although the prevalence varies in
different populations (Skre 1974; Emery 1991). CMT
involves the peripheral nerves: it gives rise to symmet-
rical, progressive weakness and atrophy of the distal
muscles, with diminished or absent tendon reflexes, and
frequently results in deformity of the feet. The disorder
can be divided into two large groups, CMT1 and CMT2,
on the basis of nerve conduction velocity (NCV) criteria.
CMT1 is characterized by a considerable decrease in
motor and sensory NCVs, with an upper limit of 38 m/
s for the motor NCV of the median nerve (Harding and
Thomas 1980). CMT1 usually results from myelin al-
teration, and histological examination often reveals
extensive segmental demyelination and remyelination
(Dyck et al. 1993). CMT2 is characterized by an NCV
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that is only slightly decreased (138 m/s) or even normal
(De Jonghe et al. 1998). It is thought that the primary
lesion in CMT2 is localized within the axon, and this
form of the disorder is often termed an “axonopathy.”
In both forms of CMT, the sensory nerves are usually
affected also, resulting in some sensory impairment.
Genetically, CMT is a very heterogeneous group of
diseases. Seventeen loci are already known to be im-
plicated in different forms of CMT and related neurop-
athies (De Jonge at al. 1997b), and further genetic het-
erogeneity seems very likely. However, thus far, only
three of the genes involved have been identified, those
for peripheral myelin protein 22 (PMP22), on chro-
mosome 17p11.2 (Lupski et al. 1991; Patel et al. 1992;
Timmerman et al. 1992; Roa et al. 1993), for myelin
protein zero (MPZ/P0), on 1q22-23 (Hayasaka et al.
1993), and for connexin 32 (Cx32/GJB1), on Xq13.1
(Bergoffen 1993). These three genes correspond to
three loci that have been designated “CMT1A” (MIM
118220), CMT1B (MIM 118200) and “CMT1X”
(MIM 302800). Recently, mutations in the early growth
response 2 (EGR2) transcription-factor gene have also
been identified in some patients with CMT1 (Warner et
al. 1998). All these proteins are closely related to myelin,
and mutations in the genes that encode them result
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mainly in CMT1. In rare cases, patients with an NCV
that is only slightly decreased also have mutations in
either Cx32 (Timmerman et al. 1996; Birouk et al.
1998) or MPZ (Marrosu et al. 1998; De Jonghe et al.
1999). However, such patients show signs of a myelin
disorder and could be considered to have a milder form
of CMT1.
Four loci implicated in autosomal dominant CMT2
have also been mapped. CMT2A (MIM 118210) maps
to chromosome 1p35-p36 (Ben Othmane et al. 1993;
Timmerman et al. 1996), CMT2B (MIM 600882) to
3q13-q22 (Kwon et al. 1995; De Jonghe et al. 1997a),
and CMT2D (MIM 601472) to 7p14 (Ionasescu et al.
1996). The fourth locus, which is implicated in the
proximal dominant form of axonal hereditary motor
and sensory neuropathy, has been assigned to the
3q13.1 region (Takashima et al. 1997, 1999). In ad-
dition to the typical features of CMT2, CMT2B is fur-
ther characterized by severe sensory abnormalities and
ulceration. In families with CMT2D families, the dis-
order commences in the upper limbs and predominantly
affects them, whereas patients with proximal axonal
neuropathy manifest an elevated creatine kinase level,
hyperlipidemia, and diabetes mellitus. However, no
causative gene has yet been identified for any of these
disorders. In this report, we describe a large family, from
the Mordovian Republic (Russia), that has autosomal
dominant CMT2. We assign the gene responsible for
the disorder in this family to chromosome 8p21, and
we have termed this locus “CMT2E.” Two neurofila-
ment genes, those for neurofilament light (NF-L
[GenBank accession number X05608]) and neurofila-
ment medium (NF-M [GenBank accession number
Y00067]), are also known to be localized to the same
region of chromosome 8p, and a missense mutation in
NF-L was found to segregate with the disorder in this
family.
Subjects and Methods
Diagnostic Criteria and Pedigree Description
A large, six-generation family with autosomal domi-
nant CMT2 was encountered in the Mordovian Repub-
lic (Russia). All members of this family considered them-
selves to be Russians. There was a clear history of
male-to-male transmission, confirming the autosomal
dominant nature of the disorder. Twenty-eight members
of the family, extending over four generations, were in-
vestigated clinically: the diagnosis of CMT2 was con-
firmed in 12 individuals and was clearly rejected in 14
others (fig. 1). All these persons were included in the
genetic analysis. The status of one adult patient (indi-
vidual IV-11 in fig. 1) was considered to be unknown,
since the diagnosis of CMT was complicated by alco-
holic neuropathy. An 8-year-old boy (individual VI-2 in
fig. 1) showed no signs of CMT, either clinically or after
electromyography (EMG) examination, but, since he
had not reached the average age at onset, he too was
considered to be of “unknown” status. However, his 10-
year-old sister (individual VI-1 in fig. 1) is considered as
being affected, despite her age, because she showed in-
itial signs of the disorder, and the diagnosis was clearly
confirmed on EMG investigation. Blood samples for mo-
lecular testing were collected after informed consent was
obtained, and the study was approved by the Scientific
Council of the Research Centre for Medical Genetics
(Moscow).
The diagnosis of CMT2 was based on the diagnostic
criteria agreed by the European CMT Consortium (De
Jonghe et al. 1998). Clinically, the most important of
these criteria are (1) a slowly progressive, symmetrical
wasting and weakness of the muscles, predominantly of
the distal part of the lower limbs; (2) decreased or absent
tendon reflexes; and (3) sensory disturbance with dif-
ferent degrees of sensory loss, including lack of sensi-
tivity to pain. A slightly reduced motor median NCV
(38–52 m/s) also was typical.
In this family, CMT2 usually manifests between the
2d and 3d decades of life, with difficulty in walking and
weakness of the leg muscles, followed by wasting of the
lower limbs and a variable degree of deformity of the
feet (all patients 120 years of age showed pes cavus, to
a greater or lesser extent). Ten family members, including
seven affected individuals, were subjected to EMG in-
vestigation: the muscle action–potential amplitude was
reduced, and there was EMG evidence of denervation
of the distal limb muscles. Six of 12 affected individuals
showed spontaneous fasciculation in limb-girdle mus-
cles. One affected individual, age 68 years, showed sig-
nificantly impaired balance, together with ptosis. Af-
fected individuals did not exhibit palpably enlarged
nerves, and there were no instances of ulcerated feet,
hearing impairment, or paralysis of the vocal cords and/
or diaphragm. We had previously described the associ-
ation of CMT and hyperkeratosis in this family (Ev-
grafov et al. 1997). However, further dermatologic
investigation of the affected members of the family con-
firmed the diagnosis of hyperkeratosis (palmoplantar
keratoderma) in only two individuals (individuals IV-10
and V-2 in fig. 1). In other individuals, the dermatologic
changes were mild or absent and did not constitute clin-
ically obvious hyperkeratosis. One individual with ap-
parently severe involvement of the skin (individual IV-
16 in fig. 1) was not examined dermatologically, and a
second, said by the family to have been similarly af-
fected, had died recently. Thus, there is no strict proof
of an association between CMT and the specific der-
matologic changes in this family, although its existence
could be suspected.
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Figure 1 Segregation analysis of markers from the NF-L - NF-M region on 8p21 in the CMT2E family. Only family members implicated
in the linkage studies are shown. The haplotypes segregating with the disease are boxed. The markers are presented in order, from telomere
(top) to centromere (bottom). The recombination event between D8S136 and the disease that occurred in the family identifies D8S136 as a
telomeric flanking marker, and recombination between NF-L(CA)n (microsatellite from the 5
′ region of NF-L) and D8S1769 in unaffected
individual IV-6 places D8S1769 centromeric to the CMT2E locus.
Genotyping
DNA was extracted from peripheral white blood cells
by a standard technique and was amplified via PCR. The
following microsatellite markers were used to test link-
age with known CMT loci: D1S2667 (AFMa224wg9),
for CMT2A; D3S1278 (AFM164xc5), D3S1292
(AFM199xd6), D3S3606 (AFMb020zb9), D3S3694
(AFMc028yb9), and D3S1279 (AFM164yg9), for
CMT2B; D7S435 (Mfd20), for CMT2D; D17S122
(RM11GT), D17S921 (AFM191xh12), and D17S261
(Mfd41), for CMT1A; and ApoA2 and D1S431
(AFM212xf6), for CMT1B. The reaction was performed
in a 25-ml reaction mix containing 0.1–0.5 mg of genomic
DNA, 0.25 mM of each primer, 200 mM of each dNTP,
1# buffer consisting of 67 mM Tris-HCl (pH 8.8), 16.6
mM (NH4)2SO4, 0.01% Tween-20, and 1 U of Taq DNA
polymerase (BioMaster). The concentration of MgCl2
was selected individually for every primer pair. Reaction
products were separated on nondenaturing 8% PAGE
and were stained with ethidium bromide prior to visu-
alization under UV light.
Linkage Analysis
Two-point linkage analysis was performed by the pro-
grams MLINK and ILINK (LINKAGE package, version
5.1) (Lathrop et al. 1984). The disorder was coded as
fully penetrant and dominant. Disease-gene frequency
was defined as .0001. Equal rates of male and female
recombination were assumed. Marker-allele frequencies
were assumed to be distributed in accordance with the
Genome Database frequency data, in Europeans, for the
marker under investigation. When this information was
not available, a uniform distribution was assumed. The
FASTLINK package (version 4.1P) was used for multi-
point analysis of data.
Mutation Analysis
Mutation screening of NF-L and NF-M was per-
formed via SSCP analysis. Since this approach is most
efficient when short fragments of DNA are being ana-
lyzed, long coding stretches of the first exon of NF-L
were amplified in six overlapping DNA fragments, the
third exon in two overlapping DNA fragments. In the
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Table 1
Oligonucleotide Primers and PCR Conditions Used for Analysis of NF-L and NF-M
GENE
PRIMER SEQUENCE
(5′r3′)
SIZE
(bp)
PCR
ANNEALING
TEMPERATURE
(C)
[MgCl2]
(mM)Forward Reverse
NF-L:
Exon 1:
Part 1: NEFL1F1: GCACACAGCCATCCATCCTCCC NEFL1R1: GATCCAGAGCTGGAGGAGTAGC 276 68 1.5
Part 2: NEFL1F2: CTTCCTCGCTGTCCGTGCGCC NEFL1R2: GCTCGTACAGCGCCCGGAAGC 279 65 1.5
Part 3: NEFL1F3: CAGAAGCACTCCGAGCCATCC NEFL1R3: CCTCGGCGTCCTCGCGGCTC 196 63 1.5
Part 4: NEFL1F4: GGAGGAGACCCTGCGCAACC NEFL1R4: CATCTCCACGGAGATCTGCGC 241 60 1.5
Part 5: NEFL1F5: CCGAACTGCAGGCGCAGATCC NEFL1R5: CTCCGACACCTCGTCCTTGGC 226 63 1.5
Part 6: NEFL1F6: GAGAGCGCCGCCAAGAACACC NEFL1R6: CCCTGTGTTTCTGGCCGTGCC 205 63 1.5
Exon 2: NEFL2F: TAATAGAAGGGATTTATGCTCGG NEFL2R: TCCTAAGGTTTAATGGCTGCTG 225 60 2.0
Exon 3:
Part 1: NEFL3F1: CCTCACCTTGCACCTGCATCC NEFL3R1: TTCGGTCTGCTCCTCTTGGAC 215 65 1.5
Part 2: NEFL3F2: CAGCTCCTATCTGATGTCCACC NEFL3R2: CACCCAGTTTACACTTGAAGTTGC 248 62 2.0
Exon 4: NEFL4F: ACTGGACTTACCCTGGATTTGC NEFL4R: CCTGATTTCGGGAGAATTATTCC 241 57 1.5
NF-M:
Exon 1:
Part 1: NEFM1F1: ACGCTGTGACAGCCACACGCC NEFM1R1: TCTGCTGCTCCAGGTAGTGCAC 411 65 1.5
Part 2: NEFM1F2: GGGCTGAACGACCGCTTTGCC NEFM1R2: TGCGATGCCTGGATCTGGGCC 440 65 1.5
Part 3: NEFM1F3: CGAGGAGGAGGTGGCCGACC NEFM1R3: CTGGCCGAGGCCGCGGTTCC 390 66 1.5
Exon 2: NEFM2F: CTGTTTGCAAGGATGAGTCTGG NEFM2R: CCACGCACGTAGTAAGCATCG 195 62 1.5
Exon 3:
Part 1: NEFM3F1: ATGTAATGAAGCTCAGAAGGCC NEFM3R1: GCCTTCTTCTTCCTCCTTTTCC 459 60 1.5
Part 2: NEFM3F2: CTCCAGTGAAAGCAACTGCACC NEFM3R2: GATTTTGGCACAGGAGACTTGGC 328 65 1.5
Part 3: NEFM3F3: AGGAGCTGGTGGCAGATGCC NEFM3R3: TCCTCTTTCTGTTCACCTTTCC 316 68 6.0
Part 4: NEFM3F4: CACCAGTGGAAGAGGCAAAGTC NEFM3R4: CTCAAGTCTAGGCCATTGGTGAC 457 58 1.5
Part 5: NEFM3F5: GGAGGGAAGAGGAGAAAGGC NEFM3R5: GCTTAACCTTTTGCAATGGACTC 315 60 2.5
a MgCl2 concentration in 1# PCR reaction buffer.
case of NF-M, exon 1 was amplified in three overlapping
fragments, exon 3 in five overlapping fragments. Ad-
ditionally, long PCR products were fragmented by re-
striction endonucleases before SSCP analysis (HaeIII for
NF-M exon 1 part 1, PvuII for NF-M exon 1 part 2,
RsaI for NF-M exon 1 part 3, Sau3AI or TaqI for exon
3 part 1, Sau3AI for NF-M exon 3 part 2, and PstI for
NF-M exon 3 part 4). Oligonucleotide primer sequences
and PCR conditions used for the analysis of NF-L and
NF-M are shown in table 1.
For SSCP analysis, PCR products were subjected to
alkaline denaturation: an aliquot of 15 ml of each am-
plified PCR product (or PCR product after restriction-
endonuclease digestion) was mixed with 5 ml of 0.5 M
NaOH and 0.5 ml of 0.5 M EDTA (pH 8.0) and was
heated at 42C for 10 min. Then 4 ml of loading buffer
(95% formamide, 0.5% bromophenol blue, and 0.5%
xylolcyanol) was added to each probe, and the samples
were loaded on nondenaturing 8% PAGE (acrylamide:
methylene-bisacrylamide ratio 29:1) either with or with-
out 5% glycerol and were electrophoresed in 0.5 x Tris-
borate EDTA at 110 V at room temperature for 18–24
h. Finally, the PAGE was stained with either ethidium
bromide or silver nitrate, by means of the Silver sequence
kit (Promega), according to standard protocol.
A band that showed altered mobility was cut off the
PAGE stained by ethidium bromide, and the correspond-
ing DNA fragment was eluted and amplified through 15
cycles. This PCR product and a normal sample were
sequenced by the dideoxy chain-termination method,
with both forward and reverse PCR primers (NEFL1F6
and NEFL1R6; see table 1). DNA sequencing was per-
formed by means of the ABI Prism dRhodamine Dye
Terminator Cycle Sequencing Ready Reaction Kit and
an ABI 310 DNA sequencer (PE Biosystems), according
to the standard protocols.
Since the identified mutation results in destruction of
the AluI site, the corresponding endonuclease was used
to test for the mutation in all family members. In ad-
dition, 180 chromosomes from 90 unrelated, unaffected
individuals of Russian ethnicity were screened for mu-
tations in the same gene fragment, by SSCP and by RFLP
analysis using AluI.
Results
Linkage Study
As a preliminary analysis, family members were
screened for linkage with known CMT2 and other
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Figure 2 Multipoint localization of CMT2E. The peak multi-
point LOD score of 6.54 was yielded by a microsatellite marker from
the 5′ region of NF-L(NF-L[CA]n). The marker loci D8S136 and
D8S1769 were fixed at a distance of 16.38 cM, and a microsatellite
marker from the 5′ region of NF-L was localized between markers
D8S136 and D8S1769, at the approximate distance of 11 cM from
D8S136. The genetic distances are inferred from the Marshfield Chro-
mosome 8 Sex-Averaged Linkage Map (D8S136 and D8S1769) and
the NIH/CEPH Chromosome 8 Linkage Map (1992) (NF-L[CA] re-
peat and D8S136), both of which are available from the Genome
Database. Kosambi’s formula was applied to convert recombination
fractions into genetic distances.
Table 2
Two-Point LOD Scores between CMT2E Locus and Microsatellite Markers on 8p21
MARKER
LOD SCORE AT RECOMBINATION FRACTION OF
MAXIMUM
LOD
SCORE
MAXIMUM
RECOMBINATION
FRACTION.00 .01 .05 .10 .20 .30 .40 .50
D8S322  .51 1.61 1.83 1.60 1.08 .47 .00 1.830 .108
D8S136 1.55 3.93 4.20 3.94 3.05 1.91 .71 .00 4.208 .040
NF-L(CA)n
a 5.93 5.83 5.40 4.84 3.67 2.40 1.05 .00 5.932 .000
D8S1769  2.34 2.75 2.67 2.16 1.48 .72 .00 2.754 .058
a Microsatellite from 5′ region of NF-L.
CMT loci. After exclusion of linkage with CMT1A
(17p11.2-p12), CMT1B (1q21-q23), CMT2A (1p35-
p36), CMT2B (3q13-q22), and CMT2D (7p14), a ge-
nomewide search was started. Possible candidate loci
were investigated first. After 25% of the genome had
been excluded in this way, significant linkage to markers
on chromosome 8p21 was detected (table 2). Recom-
bination and multipoint analyses indicated that the most
probable location of the CMT2E gene was within a 16-
cM interval flanked by markers D8S136 and D8S1769
(see figs. 1 and 2). This interval contains both NF-L and
NF-M. No recombination was detected between the dis-
ease locus and a polymorphic microsatellite repeat from
the 5′ region of NF-L, with a two-point LOD score of
5.93. NF-L and, to a lesser extent, NF-M were consid-
ered as candidate genes and were screened for mutations.
Mutation Analysis
The entire coding regions of NF-L and NF-M, in-
cluding splice sites and the promoter region, were
screened for mutations, by SSCP analysis. One mobility
shift, which cosegregated with the disorder, was found
in the first exon of NF-L. Sequencing revealed an ArC
substitution in CAG codon 333, which results in a mis-
sense mutation, Gln333Pro. This alteration destroys the
AluI restriction site, and this enzyme was used for con-
firmation of mutation and for the screening procedure
(fig. 3). An A998rC nucleotide substitution was found
in all affected members of the family but in none of their
unaffected relatives, nor was it found in 180 chromo-
somes from 90 healthy unrelated individuals. No other
DNA alterations in either NF-L or NF-M were found
that segregated with the disorder.
After this procedure, the entire coding region of NF-
L was screened for possible mutations in 46 unrelated
individuals with CMT who did not have either the
CMT1A duplication or mutations in MPZ or Cx32.
Twenty of these individuals had been diagnosed as hav-
ing CMT2, and the diagnosis had been confirmed by
EMG. In the other 26 individuals, EMG data were not
available, and these individuals were considered to rep-
resent an unspecified type of CMT. None of these in-
dividuals was found to have a mutation in NF-L.
Discussion
The clinical resemblance between different types of CMT
suggests some degree of similarity in the pathological
process. The most common type of inherited peripheral
neuropathy, CMT1A, is caused either by a duplication
of PMP22 (Lupski et al. 1991; Nelis et al. 1999) or, in
some instances, by point mutations in this gene (Val-
entijn et al. 1992; Roa et al. 1993; Nelis et al. 1999);
the mouse Trembler and Trembler-J mutations are ani-
mal models of such point mutation (Suter et al. 1992a,
1992b). The disorder results in demyelination of the pe-
ripheral nerves, accompanied by a reduction in NCV
(Adlkofer et al. 1995; Magyar et al. 1996; Thomas et
al. 1997). However, demyelination is not the direct cause
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Figure 3 Detection of A998rC nucleotide substitution in codon 333 of NF-L. A, Automated fluorescent sequence analysis of normal
(top) and mutant (bottom) alleles. The mutant allele was sequenced as “hemizygose” by means of separation, by SSCP method, of single-strand
DNA with altered mobility followed by its elution and PCR amplification. Sequencing was performed with templates of this PCR product of
the mutant allele, as well as the PCR product of normal homozygous DNA. The nucleotide substitution is denoted by the downward-pointing
arrow (f). Amino acids with codon numbers are indicated above the sequence. Recognition sites for the restriction endonuclease AluI are
underlined. B, Detection of ArC transversion in codon 333, by restriction-enzyme analysis in a part of the family with CMT2E. AluI digestion
of the wild-type NF-Lsequence yields restriction fragments of 132, 9, and 64 bp (designations 1, 4, 5, and 6; 9-bp and 64-bp fragments are
not shown). The A998C substitution destroyed one of AluI site, and, as result, the mutated allele is digested, with AluI, into 141 and 64 bp.
Both fragments—a normal one of 132 bp and an uncut one of 141 bp—are presented in the heterozygous affected members of the family with
CMT2E (designations 2, 3, 7, and 8). On the pedigree fragment, presented above the electrophoregram, the numbers of the individuals correspond
to those in the complete pedigree (see fig. 1).
of the muscle atrophy and weakness found in CMT; it
appears to act by initiating a chain of events resulting
in axonal loss and muscle denervation. It has been shown
that local axonal demyelination in Trembler mice results
in decreased neurofilament phosphorylation, slow ax-
onal transport, and reduced axonal diameter, whereas
myelinated regions of the same axon have normal pa-
rameters (de Waegh et al. 1992). Investigation of the
PMP22 duplication gives similar results (Sahenk et al.
1999). Another example of the relationship between my-
elin components and axonal function is demonstrated
by a mouse with a null mutation in the myelin-associated
glycoprotein gene (MAG). This mouse develops chronic
atrophy of myelinated peripheral-nervous-system axons,
which results in axon degeneration (Yin et al. 1998). It
is important to note that the absence of MAG correlates
with both a decrease in neurofilament phosphorylation
and reduced axonal caliber. Thus, mutations in PMP22
and MAG, the genes for myelin proteins, can both act
as signals that initiate a similar pathological process in
the axons.
Thus, neurofilament abnormality appears to be the
primary cause underlying defective axonal transport,
decreased axonal diameter, and further pathological
processes. In higher eukaryotes, there are three neuro-
filament proteins—the light, medium, and heavy neu-
rofilaments (NF-L, NF-M, and NF-H, respectively). All
three have a similar, central coiled domain, which is
responsible for the assembly of 10-nm filaments. Of the
three neurofilament proteins, NF-L seems to play the
most important role. In the first place, it is the only
neurofilament protein capable of organizing filaments
on its own (Geisler and Weber 1981; Carpenter and Ip
1996). Targeted disruption of NF-L in mice has shown
that the NF-M and NF-H subunits cannot form 10-nm
neurofilament in the absence of NF-L (Zhu et al. 1997).
Second, NF-L plays a part in regulating the expression
of the other neurofilament proteins. “Shaky” quail (Co-
turnix coturnix), which have defects in NF-L, also have
a severely reduced level of NF-M and NF-H expression
(Ohara et al. 1993). Axons in these quail vary more in
diameter, presumably affecting neuronal transmission.
Similarly, NF-L knockout mice attain only 5% of the
normal level of NF-M and NF-H expression and, like
the quail, exhibit reduced axonal radial growth. Nerve
regeneration is also delayed (Zhu et al. 1997).
It is clear that neurofilament-protein expression must
be balanced. Overexpression of either NF-M or NF-H
results in both accumulation of neurofilament proteins
in cell bodies and a decrease in axon caliber. However,
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a combined increase of NF-L with either NF-M or NF-
H promotes radial axonal growth. (Xu et al. 1996).
It is worth noting that NF-L null mutations are not
lethal in mice and do not result in a CMT-like pheno-
type. However, it is also significant that, at age 2 mo,
these mice exhibit a 15%–20% reduction in axon num-
ber. The absence of clinical CMT features may be ex-
plained either by the difference in longevity or by
absolute differences in axonal length. The nature of dif-
ferent mutations also may be important in determining
the resulting phenotype. In this regard, it is worth men-
tioning that the Leu394Pro mutation in mice has con-
sequences that are far more severe than those resulting
from a null mutation (Lee et al. 1994), despite the fact
that both amino acids belong to the same group of
neutral amino acids with nonpolar side chains. As early
as 18 d after birth, transgenic mice with this mutation
display abnormal gait, with reduced activity and weak-
ness of both upper and lower limbs. There is a per-
manent loss of mostly large, neurofilament-rich motor
axons (Lee et al. 1994; Cleveland et al. 1996), such that
this mutation could be considered an instance of gain
of function. Another interesting model is a transgenic
mouse with the human NF-H gene, which also can be
considered as a mutated version of the mouse NF-H
gene (Collard et al. 1995). Despite a low level of ex-
pression, human protein gives rise to neurological de-
fects, muscle atrophy, and neuronal neurofilament ac-
cumulation, usually explained as the effect of the human
protein on the cell.
All these data indicate that neurofilaments are im-
portant for the structure and function of axons—
particularly the larger axons—and that they may be
responsible for effective transport, axon regeneration,
and axonal longevity. Neurofilament proteins are evi-
dently key targets in axonal pathology, and the corre-
sponding genes could be considered candidate genes for
CMT.
Neurofilament proteins are involved in the pathogen-
esis of several other neurological disorders—for ex-
ample, giant axonal neuropathy (MIM 256850 [Flan-
igan et al. 1998]), amyotrophic lateral sclerosis (ALS
[MIM 105400] [Hirano 1991; Julien 1995]), Parkinson
disease (MIM 168600 and MIM 168601 [Goldman et
al. 1983; Schmidt et al. 1991b]), and Alzheimer disease
(MIM 104300 [Lee et al. 1988; Schmidt et al. 1991a;
Pollanen et al. 1994]). The common feature in all these
disorders is the accumulation of neurofilament aggre-
gates during the disease process. A rare form of axonal
hereditary motor and sensory neuropathy with neuro-
filament accumulation also has been reported (Vogel et
al. 1985). A recombinant mouse strain, which overex-
presses NF-H, shows signs of ALS-like plaques in the
brain tissue (Cote et al. 1993). Overexpression of NF-
L above a certain, specific level also results in a similar
ALS-like phenotype (Xu et al. 1993). Neurofilament
accumulation may trigger the pathological process, al-
though there is no direct evidence of this. Figlewicz et
al. (1994) reported an association between specific al-
leles of NF-H with a deletion in the KSP-motif region
and ALS, but this has not been confirmed by other in-
vestigators (Rooke et al. 1996; Vechio et al. 1996). Re-
cently, five additional mutations (four novel codon de-
letions and one insertion of 84 bp) have been found in
the COOH domain of NF-H in patients with ALS (Tom-
kins et al. 1998; Al-Chalabi et al. 1999). This suggests
that alterations in NF-H could be the primary cause of
ALS, but only in a small percentage (∼1%) of cases
(Julien 1999). Furthermore, it recently has been shown
that, at least in cases of dystonia musculorum and
SOD1-linked familial ALS, neurofilament proteins do
not play a prominent role in pathogenesis (Eyer et al.
1998). A similar situation can be found in the field of
investigation of polyglutamine disorders, where the role
of polyglutamine aggregation is not yet known (Zoghbi
and Orr 1999). Despite the clearly different cellular
mechanism in the polyglutamine disorders, the inves-
tigative pathway in both fields is surprisingly similar,
and the general structure of the still unknown gain-of-
function mechanism in both cases could be similar.
The missense mutation, Gln333Pro, is located in an
NF-L region that is conserved in mice, rats, pigs, and
cows, and this region shows high similarity in the quail
and Xenopus. Glutamine is found in the same position
in all available sequences of either NF-L or correspond-
ing proteins, even in such remote species as X. laevis.
This degree of conservation suggests the importance of
this particular amino acid for the structure or function
of the protein. Glutamine is a neutral amino acid with
a polar side chain, whereas proline has a nonpolar side
chain. The two also differ quite significantly in size. The
site of the mutation is surrounded by the protein-rod
domain, which is responsible for neurofilament assem-
bly (Carpenter and Ip 1996). More precisely, Gln333 is
located in the coil 2B domain, the last and largest of
four coil domains that form the rod region. The severe
Leu394Pro NF-L mutation in the mouse also is located
in the same coil domain. In addition, NF-L is directly
or indirectly responsible for the expression of other neu-
rofilament proteins, and this mutation also could affect
the proper regulation of such proteins. It therefore seems
probable that this mutation is the true cause of the dis-
order in this family. The fact that we failed to find any
NF-L mutation in other patients indicates that mutation
in this gene may be only a rare cause of hereditary motor
and sensory neuropathy of the axonal variety. However,
this is not unexpected. To date, four loci for CMT2
have been assigned, but none has been shown to be a
major genetic locus for the disorder (De Jonghe et al.
1998).
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It is still possible that Gln333Pro is merely a rare
genetic variant, which does not cause the disorder. At
least one more sequence variant—Asp469Asn—is
known, in the tail of the protein (subdomain B), but
this does not seem to confer a pathological phenotype
(Vechio et al. 1996). However, mutations in structural
genes can have different phenotypes, and we believe that
the arguments in favor of the pathological phenotype
of Gln333Pro are very convincing. The high LOD score
strongly confirms the localization of the pathological
gene as being within the vicinity of NF-L and NF-M.
Of all the genes and expressed sequence tags from this
region, the neurofilament genes are the only plausible
candidate genes. The only known DNA alteration in
these genes is inherited with the disorder in this family,
and this alteration is a missense mutation in the con-
served region of NF-L. A mutation in the same domain
in mice results in a pathological phenotype similar to
CMT. All these arguments strongly support the conclu-
sion that this mutation in NF-L is the true cause of the
CMT2 phenotype in the investigated family.
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